Navarro J F, Teruel J L, Mateos M, Ortuño J
Department of Nephrology, Hospital Ramón y Cajal, Madrid, Spain.
Clin Nephrol. 1994 Feb;41(2):113-6.
Hepatitis B remains a significant risk to patients receiving chronic hemodialysis. Hepatitis B vaccines are effective in providing protection against this infection. However, the minimum antibody level necessary to guarantee an efficacious protection is not clear. Little is known about the effect of this vaccine in persons treated with erythropoietin (EPO) and in patients with hepatitis C virus (HCV) infection. We have studied 36 chronic hemodialysis patients; 17 of them receiving EPO and 9 were diagnosed as having HCV infection. Effective immunity (antibody titer higher than 100 mIU/ml) was observed in 61.1% of the participants and was not influenced by EPO administration, but the effective immunization rate was lower in HCV infected patients (33.3% vs. 70.3%, p < 0.05). These results suggest the possibility that HCV infection may modify the effectiveness of hepatitis B vaccine.
乙肝对于接受慢性血液透析的患者来说仍然是一个重大风险。乙肝疫苗在预防这种感染方面是有效的。然而，保证有效防护所需的最低抗体水平尚不清楚。关于这种疫苗对接受促红细胞生成素（EPO）治疗的人以及丙型肝炎病毒（HCV）感染患者的影响知之甚少。我们研究了36名慢性血液透析患者；其中17人接受EPO治疗，9人被诊断为HCV感染。61.1%的参与者观察到有效免疫（抗体滴度高于100 mIU/ml），且不受EPO给药的影响，但HCV感染患者的有效免疫率较低（33.3%对70.3%，p<0.05）。这些结果提示HCV感染可能改变乙肝疫苗有效性的可能性。
